← Back

KPC Pharmaceuticals Inc

KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People's Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, comether tablets, specialty herbal products, classic prescription for bones and joint, antibiotics, immunosuppressive, oral products, injections, and other products, as well as engages in the wholesale and retail of medicines and equipment. The company offers products in the field of cardiovascular and cerebrovascular, orthopedics series, antimalarial, gynecology, digestive system, and others treatments. It offers its products under Luotai, Tianxuanqing, Artemedine, Artem, and Arco brands. The company was formerly known as Kunming Pharmaceutical Corporation and changed its name to KPC Pharmaceuticals, Inc. in April 2015. KPC Pharmaceuticals,Inc. was founded in 1951 and is based in Kunming, the People's Republic of China.

Price · split & dividend adjusted
News & notes moving 600422.CG
600422.CG▼3

Kunming Pharmaceutical Group reports net loss of 364 million yuan in 2026 interim report

Kunming Pharmaceutical Group released its 2026 interim report, with net profit attributable to the parent company at negative 364 million yuan, swinging from profit to loss year on year. Total operating revenue was 1.643 billion yuan, down 50.97 percent from the same period last year. Net cash flow from operating activities was negative 514 million yuan, a year-on-year decline of 334.90 percent. The latest gross margin was 19.27 percent, down 20.58 percentage points from the same period last year. Diluted earnings per share were negative 0.48 yuan. The company's latest asset-liability ratio was 41.37 percent, and the number of shareholders was 52,200.
600422.CG ▼
Jiemian·5dRead more ▾
600422.CG▲

15 Stocks Register for Dividends Today, Dazzle Fashion Leads with 4 Yuan per 10 Shares

Based on the equity registration date, a total of 15 listed companies will implement their 2025 dividend plans today. Among them, 10 companies have a cash dividend of 1 yuan or more per 10 shares. Dazzle Fashion is the most generous, distributing 4.00 yuan per 10 shares, followed by COSCO Shipping Specialized Carriers and Huaxia Bank, with cash dividends of 3.25 yuan and 3.20 yuan per 10 shares respectively. In terms of share transfers, Chengzhi Shareholding has the highest ratio, with a transfer of 4 shares for every 10 shares held. Regarding recent stock performance, KPC Pharmaceuticals has led these 15 stocks with a cumulative gain of 3.76% over the past five trading days.
000990.CS ▲603587.CG ▲600015.CG ▲600428.CG ▲600422.CG ▲
证券时报·29dRead more ▾
600422.CG▼

KPC Pharmaceuticals Plans to Sell Up to 2.44 Million Shares in Vinet Biotech, Expected Transaction Value of 132 Million Yuan

KPC Pharmaceuticals announced plans to sell up to 2.44 million shares in Vinet Biotech through methods such as centralized bidding and block trades, with an expected transaction value of 132 million yuan and a book cost of 113 million yuan. In the first quarter of 2026, KPC Pharmaceuticals achieved revenue of 836 million yuan, with a net loss attributable to the parent company of 142 million yuan.
600422.CG ▼
财中社·34dRead more ▾
600422.CG▼2

KPC Pharmaceuticals Plans to Sell Up to 2,443,022 Shares of Leed Biotech

KPC Pharmaceuticals announced that, in order to further strengthen its core business and optimize its asset structure, the company plans to sell up to 2,443,022 shares of Nanjing Leed Biotech Co., Ltd. through methods such as centralized bidding and block trades at an opportune time.
600422.CG ▼
证券时报·34dRead more ▾
© 2026 MarketDXAsset